How is cystic fibrosis diagnosed? 

Cystic fibrosis is primarily identified through a series of structured clinical tests designed to detect genetic markers and physical indicators of the condition. In the United Kingdom, the diagnostic pathway typically begins at birth, though it can be initiated at any stage of life if symptoms suggest the presence of the disorder. The process involves a combination of screening, biochemical analysis of sweat, and detailed genetic mapping to ensure an accurate diagnosis and allow for the early commencement of specialist care. By identifying the condition early, healthcare teams can implement nutritional and respiratory support that significantly improves long-term outcomes for the patient. 

What We’ll Discuss in This Article 

• The role of the newborn blood spot test in early detection. 

• How the sweat test confirms elevated salt levels in the skin. 

• Genetic testing for identifying specific CFTR mutations. 

• Clinical signs that may trigger a diagnosis in older children or adults. 

• The importance of specialist referral following a positive result. 

• Understanding inconclusive results and carrier status in the UK. 

Newborn blood spot screening 

The majority of cystic fibrosis cases in the United Kingdom are now identified within the first few days of life through the national newborn screening programme. The NHS newborn blood spot test, often called the heel prick test, is offered to all babies when they are five days old to check for several rare but serious conditions including cystic fibrosis. During this procedure, a midwife or healthcare professional pricks the baby’s heel to collect a few drops of blood on a special card. This sample is then sent to a laboratory to measure the level of a chemical called immunoreactive trypsinogen (IRT). 

IRT is a protein produced by the pancreas. In babies with cystic fibrosis, the small ducts in the pancreas can become blocked by thick mucus even before birth, causing IRT to leak into the bloodstream in higher than normal amounts. While a high level of IRT can be a significant indicator of cystic fibrosis, it is not a definitive diagnosis on its own, as high levels can also be caused by a difficult birth or other temporary health factors. If the IRT level is found to be high, the laboratory will often perform a genetic test on the same blood sample to look for the most common mutations. 

The confirmatory sweat test 

The sweat test is the standard and most reliable diagnostic tool used to confirm a diagnosis of cystic fibrosis if a screening test or clinical symptoms suggest the condition. A sweat test measures the amount of chloride in a sample of sweat, as people with cystic fibrosis have significantly higher levels of salt than the general population. This is due to the faulty CFTR protein, which normally helps move salt to the skin’s surface but fails to reabsorb it correctly in those with the condition. 

During the test, a small amount of a sweat-inducing chemical called pilocarpine is applied to a small patch of skin, usually on the forearm. A very weak electrical current is then used to help the chemical reach the sweat glands, a process known as iontophoresis. This is not painful, though it may cause a slight tingling sensation. The sweat is then collected onto a piece of filter paper or a special plastic coil over a period of approximately 30 minutes. Once the sample is collected, it is analysed in the biochemistry lab. A chloride level of 60 mmol/L or higher is typically used to confirm a diagnosis, while a result between 30 and 59 mmol/L is considered “borderline” and may require further investigation. 

Genetic testing and mutation analysis 

Genetic testing is used alongside the sweat test to identify the specific mutations in the CFTR gene that are causing the condition. NICE guidance recommends that genetic testing should be performed to confirm a diagnosis and to identify the specific genotype, which is increasingly important for accessing targeted treatments. This test usually involves a simple blood sample or, occasionally, a swab from the inside of the cheek. In the UK, laboratories typically test for a panel of the most common mutations found in the British population, including the Delta F508 mutation. 

Because there are over 2,000 known mutations that can cause cystic fibrosis, a standard genetic screen may not identify every single one. If a person has a clear positive sweat test but only one (or no) common mutation is found, the specialist team may request “full gene sequencing.” This is a more detailed analysis that looks at the entire length of the CFTR gene to find rarer variations. Identifying the specific mutation is now a vital part of diagnosis because many modern medications, known as CFTR modulators, are only effective for certain genetic types. 

Diagnosis in older children and adults 

While newborn screening has made early diagnosis the norm since its UK-wide rollout in 2007, some individuals with milder mutations or those born before that date may not be diagnosed until later in childhood or adulthood. According to the NHS, a diagnosis later in life may be triggered by persistent symptoms such as recurrent chest infections, difficulty gaining weight, or male infertility. In adults, the condition might present as “atypical” cystic fibrosis, where the individual may have normal or borderline sweat test results but persistent respiratory or digestive issues. 

Common triggers for investigating an adult for cystic fibrosis include the development of bronchiectasis (widening of the airways), chronic sinusitis with nasal polyps, or recurring bouts of pancreatitis. In some men, the condition is first suspected during fertility investigations that reveal a congenital bilateral absence of the vas deferens (CBAVD), which prevents sperm from being transported. In all these cases, a specialist referral for a sweat test and detailed genetic mapping is the standard clinical pathway to either confirm or rule out the condition. 

Managing inconclusive results (CFSPID) 

In some instances, a baby may have a positive newborn screening result, but the follow-up tests do not provide a clear-cut diagnosis of cystic fibrosis. This situation is known as Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID), where a child may have some features of the condition but does not meet the full clinical criteria. For example, a baby might have two genetic mutations, but one of them is known to only cause very mild or no symptoms, and their sweat test result might be in the normal or borderline range. 

Children with CFSPID are typically monitored by a specialist cystic fibrosis team because, while many will remain entirely healthy throughout their lives, a small number may develop symptoms of the condition as they grow older. This monitoring allows the specialist team to intervene immediately if any respiratory or digestive issues appear. Parents of children with CFSPID are given specific guidance on what signs to look for, such as a persistent cough or poor weight gain, and are provided with a direct line of communication to the specialist centre. 

Referral to specialist cystic fibrosis centres 

Once a diagnosis is suspected or confirmed through screening and confirmatory tests, the individual is referred to a specialist cystic fibrosis centre. NICE guidelines state that anyone with a positive or equivocal sweat test result or a confirmed genetic mutation should be referred to a multidisciplinary specialist team. These centres are staffed by experts who specialise solely in the management of this condition, ensuring that the patient receives the highest standard of care from the outset. 

The specialist team at these centres includes respiratory doctors, specialist nurses, physiotherapists, dietitians, and clinical psychologists. During the initial appointment, the team will perform a baseline assessment of the patient’s lung health and nutritional status. For infants, this often involves starting on prophylactic antibiotics to prevent lung infections and beginning pancreatic enzyme supplements to support weight gain. The team also provides essential education to the family, teaching them how to perform daily airway clearance and how to manage the various medications required to keep the child healthy. 

Test Type	Timing in the UK	Primary Function
Blood Spot Test	5 days old	Routine screening for elevated IRT levels.
Sweat Test	Any age	Measures chloride levels to confirm diagnosis.
Genetic Test	Any age	Identifies specific mutations for treatment planning.
Faecal Elastase	At diagnosis	Checks if the pancreas is producing enough enzymes.

The importance of early intervention 

The primary goal of the UK’s diagnostic framework is to ensure that treatment begins before significant damage to the lungs or digestive system occurs. Historically, children were often only diagnosed once they became visibly unwell or failed to grow, by which time they might already have experienced several severe lung infections. With modern screening and rapid confirmatory testing, most infants start their treatment plan within the first few weeks of life. This proactive approach has been a major factor in the significant increase in life expectancy and the improved quality of life for people living with cystic fibrosis today. 

Conclusion 

The diagnosis of cystic fibrosis in the UK is a highly structured and effective process that prioritises early detection. While the newborn heel prick test serves as the primary screening tool, the sweat test and genetic analysis remain the definitive methods for confirming the condition. Whether diagnosed in infancy or adulthood, the focus remains on a rapid transition to specialist multidisciplinary care to ensure the best possible long-term health outcomes. Consistent monitoring and access to the latest genetic-led therapies are the pillars of modern cystic fibrosis management. 

If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article outlines the clinical diagnostic pathway for cystic fibrosis as defined by the UK’s national screening and care standards. The content is developed by a medical writing team and has been reviewed by Dr. Rebecca Fernandez, a UK-trained physician with extensive experience in internal medicine and emergency care. All information presented is strictly aligned with current NHS and NICE clinical guidance to ensure medical safety and accuracy for all readers.